GeneInCell

Optogenetics has transformed neuroscience by letting scientists control specific nerve cells with light. In this episode, we explore the discoveries behind the 2026 Nobel Prize in Physiology or Medicine, how light-sensitive ion channels became powerful tools for mapping brain circuits, and how optogenetics is opening new possibilities for understanding—and potentially treating neurological and sensory disorders.

AlphaGenome Atlas is helping decode the 98% of the human genome that doesn’t code for proteins. By predicting how non-coding variants affect transcription, splicing, chromatin accessibility, and gene regulation, it can prioritize potentially harmful mutations, clarify rare disease cases, and reveal regulatory mechanisms hidden in the “dark genome.”

Can mRNA vaccines train the immune system to recognize and attack cancer? In this episode, we explore how mRNA cancer vaccines are designed, how they deliver tumor-specific instructions to immune cells, and why personalized neoantigen vaccines are gaining attention. We also cover current clinical progress, the potential to combine mRNA vaccines with immunotherapy, and the challenges that remain to be solved before these approaches become routine cancer treatments.

Can peptides help slow the biological processes of aging? In this episode, we explore how anti-aging peptides may influence cellular repair, inflammation, metabolism, collagen production, and tissue regeneration. We examine the scientific evidence, emerging therapeutic applications, and the limitations and safety concerns surrounding peptide-based approaches to healthier aging.

Telomerase helps protect the ends of chromosomes, but its role in aging is complex. In this episode, we explore how telomeres influence cellular lifespan, whether activating telomerase could slow age-related decline, and the scientific and safety challenges that stand between promising research and future anti-aging therapies.

Epigenetic reprogramming is emerging as one of the most intriguing ideas in aging research—the possibility that aging is not just damage, but also a reversible loss of cellular identity. In this episode, we explore how scientists are trying to reset the epigenetic instructions that control gene expression, tissue function, and biological age. We break down the science behind partial reprogramming, what preclinical studies suggest about rejuvenation, regeneration, and lifespan-related outcomes, and why safety, durability, and cancer risk remain major challenges. Can aging really be reversed, or are we only beginning to understand the code that drives it?

Aptamers are emerging as powerful “chemical antibodies” that can bind targets with high precision while offering advantages in design, synthesis, and stability. In this episode, we explore how these short nucleic acid ligands are selected, how they work, and why they are gaining attention as next-generation tools for diagnostics, targeted delivery, and therapy. We also discuss their potential to reshape future medicine, along with the key challenges that must be solved for broader clinical use.

Antisense oligonucleotides are redefining medicine by programming RNA to silence disease at its source. In this episode, we explore how these short, sequence-designed molecules bind target RNA to reduce harmful protein production, reshape splicing, and open new possibilities for precision therapeutics. We cover the history, mechanism, chemistry, and growing clinical relevance of ASOs, along with their promise and limitations in treating genetic, neurological, retinal, muscular, liver, and rare diseases.

shRNA is a gene-silencing tool that uses the cell’s own RNA interference machinery to reduce harmful protein production. In this episode, we explore how short hairpin RNAs are designed to target specific mutant genes, how they are delivered into cells, and why they hold promise for treating genetic disease through long-lasting gene knockdown.

Base editing is changing the future of gene editing by allowing scientists to rewrite DNA one letter at a time. In this episode, we explore how base editors work, why they offer a more precise alternative to traditional CRISPR cutting, and how they are being used to correct disease-causing mutations. We also look at their growing potential in research and medicine, along with the challenges that remain for safe and effective clinical use.

siRNAs are transforming medicine by acting as programmable drugs that selectively silence disease-causing genes. In this episode, we explore how small interfering RNAs work through the RNA interference pathway, why they are so powerful for precision therapeutics, and how they are being developed to treat genetic, metabolic, liver, and rare diseases. We also discuss delivery challenges, clinical progress, and what makes siRNA one of the most promising platforms in modern drug development.

Prime editing is a next-generation gene editing tool designed to precisely rewrite DNA—like a search-and-replace function for the human genome. In this episode, we break down how prime editing works, the chemistry behind it, and why it offers a powerful alternative to traditional CRISPR by making targeted changes without creating double-strand breaks. We also explore its applications in disease correction, its growing path toward the clinic, and the key challenges that still stand in the way.

NAMs are changing how new drugs are developed. We discuss organoids, tissue chips, and AI-based tools, along with the growing FDA and NIH push toward more human-relevant methods that can improve prediction, reduce reliance on animal models, and help bring safer treatments forward faster.

Can we grow new kidneys from stem cells? In this episode, we explore how scientists are using pluripotent stem cells to create kidney organoids that mimic early kidney development. We discuss how these mini-organs help study kidney disease, test new drugs, and move us closer to future regenerative therapies for kidney failure.

What really happens to your cells under stress, in space, and during space travel? In this episode, we zoom in on the physiological, cellular, and molecular levels to uncover how zero gravity affects them.

What does it take to grow a beating human heart in the lab? This episode explores cardiac organoids—self-organizing heart tissues derived from human stem cells that contract, respond to drugs, and model human heart disease. We unpack how iPSCs are guided into cardiac lineages, how electrical and mechanical cues drive maturation, and why these beating mini-hearts are transforming drug safety testing, disease modeling, and the future of regenerative cardiology.

In this episode, we explore the AI revolution in healthcare and what 2026 could look like—from smarter diagnostics and personalized treatments to automation that reshapes clinical workflows. We break down the key innovations, emerging trends, and real-world impact of AI on patients, clinicians, and the healthcare system.

Synthetic biology is turning cells into programmable factories, sensors, and therapies. In this episode, we explore how DNA can be engineered like code to build smarter medicines, sustainable biomaterials, and living devices—and what it will take to move these innovations from the lab to the real world.

How do you give “mini-brains” a bloodstream? This episode explores vascular brain organoids—cerebral organoids engineered with endothelial cells, pericytes, and astrocytes to form BBB-like barriers, improve oxygen/nutrient delivery, and accelerate neuronal maturation. We cover why perfusion matters for MEA activity and drug testing, how microvessels enable neurovascular-coupling studies, and what it will take to scale these tissues for translational neuroscience.

Brain organoids are self-organizing “mini-brains” grown from human stem cells that recapitulate key aspects of early neural development. They fire neural networks on MEAs, model neurodevelopmental and neurodegenerative diseases, and offer human-relevant platforms for drug discovery, circuit mapping, and studying brain evolution—while raising important questions about maturity, reproducibility, and ethics.